BIMEKIZUMAB TREATMENT RESULTED IN LONG-TERM EFFICACY AND SAFETY IN BIOLOGICAL-NA&#207;VE PATIENTS WITH ACTIVE PSORIATIC ARTHRITIS: WEEK 192 END-OF-TRIAL RESULTS FROM THE BE OPTIMAL PHASE 3 STUDY AND ITS OPEN-LABEL EXTENSION

Bimzelx (bimekizumab-bkzx) - UCB

Humira (adalimumab) - AbbVie

https://distribution-congress.eular.org/from.storage?image=15rRXWmdOAJ77zPlkD-rQsC2mqNo7Rs4bGkaQaWkPyFbCUSSSXYw76-aLl5yrnwI0

Laura C. Coates 1; Laure Gossec2; Iain B. McInnes3; Joseph F Merola4; Hideto Kameda5; Yoshiya Tanaka6; Vinod Chandran7; Kurt de Vlam 8; Fabian Proft9; Akihiko Asahina10; Barbara Ink11; Rajan Bajracharya11; Jason Coarse 12; Philip J. Mease13

May 23, 2026